Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results